Avita Medical stock (US0301011039): Q1 2026 results and revenue details
Avita Medical reported its Q1 2026 financial results on May 14, 2026, providing key insights into its revenue trends and demand for wound care products. The company's business model is centered on therapeutic acute wound care, with products aimed at hospitals and clinical settings in the U.S., Japan, Europe, Australia, and the U.K. Investors are keenly watching these reports for signs of product adoption, commercial reimbursement, and operational leverage, as well as the impact of its Nasdaq and ASX listings.
APR 1·Stock Titan→
AVITA Medical (RCEL) files $200M S-3 shelf to sell stock, warrants
AVITA Medical, Inc. (RCEL) has filed an S-3 shelf registration statement to offer up to $200 million in common stock, preferred stock, warrants, and units. The company intends to use the net proceeds for general corporate purposes, including capital expenditures and working capital. Specific terms of each offering, such as pricing and distribution methods, will be detailed in future prospectus supplements.
FEB 23·MarketBeat▲
Avita Medical (NASDAQ:RCEL) CFO David O'toole Purchases 3,000 Shares of Stock
Avita Medical (NASDAQ:RCEL) CFO David O'toole recently purchased 3,000 shares of the company's stock for $12,450, increasing his total holdings to 140,127 shares. The transaction, disclosed in an SEC filing, reflects a 2.19% increase in his position. The stock traded up by 1.3% to $4.85 following the news, with the company currently holding a "Hold" consensus rating from analysts.
